Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Palatal oral mucosa (POM) is an autologous tissue graft harvested from a patient's palate and surgically transplanted to another site in the oral cavity. In the clinical research conducted by Dr. Stephen E. Feinberg at the University of Michigan, POM serves as the standard-of-care control for evaluating the efficacy of tissue-engineered constructs like EVPOME (Ex Vivo Produced Oral Mucosa Equivalent). It is primarily used to augment keratinized oral mucosa around dental implants and natural teeth, providing a stable biological environment to prevent soft tissue recession and maintain oral health. As an autogenous graft, it contains the patient's own keratinocytes and connective tissue matrix, ensuring high biocompatibility and structural integrity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on palatal oral mucosa.